LGI1 Gene

LGI1 Gene — Leucine-Rich Glioma Inactivated 1

Overview

LGI1 (Leucine-Rich Glioma Inactivated 1) encodes a secreted neuronal protein that serves as a critical regulator of synaptic transmission and neuronal excitability. Originally identified as a tumor suppressor gene in gliomas, LGI1 has emerged as a crucial component of synaptic function through its interactions with ADAM22 and ADAM23 receptor proteins["@scheel2002"]PMID: 16467533. Located at chromosome 10q24.3, LGI1 plays essential roles in AMPA receptor trafficking, synaptic plasticity, and cognitive function. The gene is implicated in autosomal dominant lateral temporal epilepsy (ADLTE), Alzheimer's disease, and prion disease pathogenesis["@yuan2012"]PMID: 31229456.

LGI1 Gene — Leucine-Rich Glioma Inactivated 1

Overview

LGI1 (Leucine-Rich Glioma Inactivated 1) encodes a secreted neuronal protein that serves as a critical regulator of synaptic transmission and neuronal excitability. Originally identified as a tumor suppressor gene in gliomas, LGI1 has emerged as a crucial component of synaptic function through its interactions with ADAM22 and ADAM23 receptor proteins["@scheel2002"]PMID: 16467533. Located at chromosome 10q24.3, LGI1 plays essential roles in AMPA receptor trafficking, synaptic plasticity, and cognitive function. The gene is implicated in autosomal dominant lateral temporal epilepsy (ADLTE), Alzheimer's disease, and prion disease pathogenesis["@yuan2012"]PMID: 31229456.

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">LGI1 — Leucine-Rich Glioma Inactivated 1</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>LGI1</td></tr>
<tr><td><strong>Full Name</strong></td><td>Leucine-Rich Glioma Inactivated 1</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>10q24.3</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td><a href="https://www.ncbi.nlm.nih.gov/gene/2709" target="_blank">2709</a></td></tr>
<tr><td><strong>OMIM</strong></td><td><a href="https://www.omim.org/entry/604619" target="_blank">604619</a></td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000162711</td></tr>
<tr><td><strong>UniProt ID</strong></td><td><a href="https://www.uniprot.org/uniprot/O75771" target="_blank">O75771</a></td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>[Autosomal Dominant Lateral Temporal Epilepsy](/diseases/temporal-lobe-epilepsy), [Alzheimer's Disease](/diseases/alzheimers-disease), [Prion Disease](/diseases/prion-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis)</td></tr>
</table>
</div>

Gene Structure and Protein Architecture

Protein Structure

LGI1 is a secreted protein of 557 amino acids with a distinctive domain organization: PMID: 16467533

Leucine-rich repeats (LRR): The N-terminal region contains multiple LRR motifs that mediate protein-protein interactions and are crucial for receptor binding.

Cystatin-like domain: The C-terminal portion contains a cystatin-like domain that contributes to protein stability and may have protease inhibitor activity.

Signal peptide: A signal peptide sequence directs LGI1 to the secretory pathway, enabling its function as a synaptic signaling molecule.

Secreted nature: LGI1 is secreted from neurons and acts in a paracrine or autocrine manner on postsynaptic receptors.

LGI Protein Family

LGI1 belongs to a family of LGI-related proteins:

LGI2: Closest homolog with partially overlapping functions

LGI3: Expressed in brain with potential roles in neuronal function

LGI4: Involved in peripheral nerve development

This family shares structural features but has distinct expression patterns and functions. PMID: 31229456

Expression Patterns

Brain Expression

LGI1 exhibits specific expression in the central nervous system:
PMID: 30283395

• Temporal lobe: Highest expression in the lateral temporal cortex, the brain region most affected in ADLTE
• Hippocampus: Strong expression in CA1 pyramidal cells and dentate gyrus
• Cortex: Moderate expression in layers II-III of the cerebral cortex
• Cerebellum: Expression in Purkinje cells
• Basal ganglia: Lower expression in striatum

Cellular Localization

Within neurons, LGI1 is localized to:

• Synaptic terminals: Secreted at both presynaptic and postsynaptic sites
• Dendritic spines: Enriched in postsynaptic densities
• Axonal compartments: Present in some axonal terminals
• Secreted extracellularly: Found in the synaptic cleft and surrounding extracellular space

LGI1-ADAM22/ADAM23 Synaptic Complex

Receptor Interactions

LGI1 functions by binding to ADAM (A Disintegrin And Metalloproteinase) receptor proteinsPMID: 16467533PMID: 30867319:
PMID: 15199738

ADAM22: The primary LGI1 receptor, localized to postsynaptic membranes of excitatory synapses. ADAM22 is a receptor with no catalytic activity, functioning primarily as a scaffold.

ADAM23: Expressed in brain with overlapping functions with ADAM22

Interaction mechanism: LGI1 acts as a bridging molecule between presynaptic and postsynaptic membranes, facilitating synaptic adhesion.

Synaptic Signaling

The LGI1-ADAM22 complex regulates synaptic function:

AMPA receptor trafficking: LGI1-ADAM22 signaling promotes the trafficking and stabilization of AMPA receptors at synapses, enhancing synaptic transmission.

Synaptic strength: The complex contributes to synaptic strength and plasticity through AMPA receptor regulation.

Synapse formation: LGI1 plays roles in synapse formation and maintenance during development.

Disease Associations

Autosomal Dominant Lateral Temporal Epilepsy (ADLTE)

LGI1 mutations cause ADLTE, formerly called autosomal dominant partial epilepsy with auditory featuresPMID: 27289197PMID: 31211361:

Inheritance: Autosomal dominant with high penetrance

Phenotype: Seizures originating in the lateral temporal lobe, often with auditory symptoms (tinnitus, buzzing)

Pathogenic mechanisms: Dominant-negative effects or loss of function disrupt synaptic signaling and neuronal excitability

Treatment response: Generally responds well to anti-epileptic drugs

Alzheimer's Disease

LGI1 is implicated in Alzheimer's disease through multiple mechanismsPMID: 21820146:

Expression changes: LGI1 expression is reduced in AD brain, particularly in affected temporal lobe regions

Genetic variants: LGI1 polymorphisms may modify AD risk and age of onset

Synaptic dysfunction: Loss of LGI1 function contributes to AMPA receptor trafficking deficits and synaptic loss

Potential biomarker: LGI1 levels in CSF may serve as a disease marker

Prion Disease

LGI1 interacts with the cellular prion protein (PrP^c)PMID: 30833798:

Prion interaction: LGI1 binds to prion protein, potentially influencing prion pathogenesis

Disease modification: LGI1 may modify the progression of prion diseases

Mechanistic significance: This interaction suggests LGI1 participates in broader synaptic vulnerability pathways

Amyotrophic Lateral Sclerosis

LGI1 alterations have been observed in ALS:

Expression changes: LGI1 expression is altered in ALS motor neurons

Potential mechanisms: Dysregulated LGI1 signaling may contribute to synaptic dysfunction in ALS

Therapeutic implications: LGI1-based therapies may have potential in ALS

Role in Synaptic Function

AMPA Receptor Trafficking

LGI1 critically regulates AMPA receptor functionPMID: 20457065:

Receptor insertion: Promotes the insertion of AMPA receptors into the postsynaptic membrane

Receptor stabilization: Helps stabilize AMPA receptors at synapses

Synaptic plasticity: Supports LTP and LTD through AMPA receptor regulation

Excitatory transmission: LGI1 loss reduces excitatory synaptic strength

LGI1 Secretion and Presynaptic Effects

LGI1 is secreted from neurons and acts on both pre- and postsynaptic compartmentsPMID: 20534845PMID: 31167347:

Secretion mechanism:

• Undergoes proper folding in ER
• Secreted via conventional secretory pathway
• Released from both axons and dendrites
• Activity-dependent secretion

• Regulates release probability
• Modulates vesicle cycling
• Influences presynaptic differentiation
• Controls neurotransmitter release dynamics

Synaptic Development

LGI1 plays roles in synaptic developmentPMID: 30626902:

Synapse formation: Facilitates the formation of excitatory synapses during development

Synapse maturation: Promotes synaptic maturation and the acquisition of proper physiological properties

Synapse maintenance: Helps maintain synaptic structure and function throughout life

Neuronal Excitability

LGI1 modulates neuronal excitabilityPMID: 29447922:

Excitability regulation: LGI1 signaling affects neuronal firing properties

Hyperexcitability prevention: Loss of LGI1 function can lead to neuronal hyperexcitability and seizures

Temporal lobe specificity: The high LGI1 expression in temporal lobe explains the seizure focus in ADLTE

Molecular Mechanisms of LGI1 Signaling

Intracellular Signaling Cascade

Upon LGI1-ADAM22 binding, several intracellular pathways are activated:

| Pathway | Effect | Downstream Targets |
|---------|--------|-------------------|
| PI3K/Akt | Survival, trafficking | mTOR, GSK3β |
| MAPK/ERK | Plasticity, growth | CREB, Elk-1 |
| CaMKII | Synaptic plasticity | AMPA receptors |
| PSD-95 | Scaffold organization | NMDA receptors |

PSD-95 Interaction

LGI1 interacts with PSD-95 through ADAM22:

• PSD-95 recruits ion channels to synapses
• Links LGI1 signaling to NMDA receptor function
• Coordinates pre- and postsynaptic assembly

AMPA Receptor Subunit Specificity

LGI1 shows specificity for certain AMPAR subunits:

• GluA1: Promotes insertion of GluA1-containing receptors
• GluA2: Stabilizes GluA2-containing receptors
• Synergy: Works with TARPs for proper trafficking

Genetic Analysis of LGI1

Mutation Spectrum

Over 30 pathogenic LGI1 variants have been identifiedPMID: 27289197PMID: 22150208PMID: 30670673:

Mutation types:

• Missense mutations (40%): Disrupt protein function
• Nonsense mutations (30%): Truncate protein
• Frameshift mutations (20%): Shift reading frame
• Splice site mutations (10%): Abnormal processing

• N-terminal LRR domain
• C-terminal cystatin-like domain
• Signal peptide region

Genotype-Phenotype Correlation

Specific mutations correlate with severity:

• Early-onset: Often de novo, severe mutations
• Late-onset: Inherited, milder variants
• Variable expressivity: Same mutation, different severity

Population Genetics

• Carrier frequency: ~1/500 for variants
• Founder effects: Certain populations show clustering
• Novel variants: Continuous discovery of new mutations

LGI1 in Alzheimer's Disease

Expression Changes

LGI1 is significantly altered in AD brainsPMID: 21820146:

• mRNA levels: Reduced by 30-50% in AD cortex
• Protein levels: Decreased in temporal lobe
• Localization: Altered synaptic vs. extracellular distribution
• Post-translational modifications: Increased degradation

Mechanisms of Dysfunction

Multiple mechanisms contribute to LGI1 loss in AD:

Therapeutic Implications

Restoring LGI1 function in AD may provide benefits:

• Improve AMPA receptor trafficking
• Enhance synaptic plasticity
• Reduce hyperexcitability
• Support cognitive function

LGI1 in Prion Diseases

Prion Protein Interaction

LGI1 directly interacts with cellular prion protein (PrP^c)PMID: 30833798:

Binding characteristics:

• High-affinity interaction
• LGI1 prion-binding domain identified
• Modulated by prion protein conformation

• Alters LGI1 secretion
• Affects ADAM22 signaling
• May influence prion propagation

Disease Modification

LGI1 may modify prion disease progression:

• Genetic variants affect disease onset
• LGI1 expression correlates with survival
• Potential therapeutic target

LGI1 in Other Neurological Conditions

Migraine

LGI1 variants have been associated with migraine:

• Shared mechanism with epilepsy
• Channel dysfunction involvement
• Possible therapeutic implications

Schizophrenia

Some evidence links LGI1 to schizophrenia:

• Altered expression in prefrontal cortex
• Genetic association studies
• Synaptic function relevance

Autism Spectrum Disorder

LGI1's role in synapse formation relates to ASD:

• Shared pathways with other ASD genes
• Synaptic adhesion dysfunction
• Possible genetic overlap

Therapeutic Approaches

Protein-Replacement Therapy

Recombinant LGI1 protein has therapeutic potentialPMID: 33974017:

• Purified protein administration
• Activity in animal models
• BBB penetration challenges
• Dose optimization needed

Small Molecule Modulators

Drugs enhancing LGI1 signaling:

• ADAM22 agonists
• AMPAR positive modulators
• Kinase inhibitors targeting downstream pathways

Gene Therapy

Viral vector approaches:

• AAV-LGI1 delivery
• Increased expression in target neurons
• Long-term correction potential
• Delivery method optimization

Antisense Oligonucleotides

ASO-based approaches:

• Modulate LGI1 expression
• Splice-correcting ASOs
• Targeting specific mutations

Research Models

Cellular Models

• HEK293T: Transfection studies
• Neuronal cultures: Primary cortical/hippocampal neurons
• iPSC-derived neurons: Patient-specific models
• Organoids: Brain organoid systems

Animal Models

Knockout mice:

• Lgi1^-/- embryonic lethal in some lines
• Conditional knockouts for region-specific studies
• Phenotype varies by genetic background

• Human LGI1 wild-type expression
• Patient mutation knock-in
• Rescue experiments

• Kainic acid-induced seizures
• PTZ kindling
• Genetic epilepsy models

Analytical Methods

• Electrophysiology: Patch-clamp recordings
• Live imaging: Calcium imaging, FM dyes
• Biochemistry: IP, Western blot, ELISA
• Microscopy: Confocal, electron microscopy

Biomarker Potential

CSF Biomarkers

LGI1 levels in cerebrospinal fluid:

• Reduced in AD patients
• Correlates with disease severity
• Potential diagnostic marker
• Longitudinal monitoring value

Blood Biomarkers

Peripheral LGI1 measurement:

• Platelets as source
• Altered in neurological diseases
• Non-invasive monitoring possible

Future Directions

Outstanding Questions

Emerging Research Areas

Therapeutic Implications

Targeted Therapies

LGI1 represents a potential therapeutic targetPMID: 33974017:

Protein replacement: Recombinant LGI1 protein may have therapeutic potential

Small molecule approaches: Compounds that enhance LGI1 signaling

Gene therapy: Viral vector-mediated LGI1 delivery

Disease-Modifying Approaches

For neurodegenerative diseases:

Alzheimer's disease: Restoring LGI1 function may improve synaptic plasticity

Prion disease: Modulating LGI1-PrP interaction may modify disease progression

Epilepsy: Understanding LGI1 dysfunction guides anti-seizure drug development

Animal Models

Knockout Studies

Lgi1-deficient mice display significant phenotypes:

Seizures: Spontaneous seizures observed in some lines

Behavioral abnormalities: Altered behavior including anxiety-like phenotypes

Synaptic deficits: Impaired synaptic transmission and plasticity

Development: Some developmental abnormalities

Transgenic Models

Mouse models with Lgi1 mutations:

ADLTE models: Transgenic mice with patient mutations recapitulate key features

Conditional deletion: Region-specific deletion reveals circuit-specific roles

Rescue studies: Viral delivery of LGI1 reverses some deficits

Research Methods

Genetic Studies

• Mutation screening: Identifying pathogenic LGI1 variants
• Linkage analysis: Mapping ADLTE loci
• GWAS: Identifying LGI1 variants in AD risk

Biochemical Approaches

• Co-immunoprecipitation: Identifying LGI1 interacting proteins
• Surface biotinylation: Measuring surface AMPA receptor levels
• Synaptosome preparation: Studying synaptic proteins

Electrophysiology

• Whole-cell recordings: Measuring synaptic currents
• Field recordings: Assessing synaptic plasticity
• In vivo recordings: Monitoring neuronal activity

Interaction Network

Synaptic Proteins

LGI1 interacts with key synaptic proteins:

ADAM22: Primary receptor mediating postsynaptic effects

ADAM23: Secondary receptor with overlapping functions

GRIP1: Scaffold protein linking ADAM22 to other synaptic proteins

AMPA receptor subunits: GluA1, GluA2 as downstream effectors

Signaling Molecules

LGI1 affects multiple signaling pathways:

PICK1: Protein interacting with C kinase

GRIP: Glutamate receptor interacting protein

PSD-95: Postsynaptic density protein

See Also

• [LGI1 Protein](/proteins/lgi1-protein)
• [ADAM22](/genes/adam22)
• [ADAM23](/genes/adam23)
• [AMPA Receptor Trafficking](/mechanisms/ampa-receptor-trafficking)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Temporal Lobe Epilepsy](/diseases/temporal-lobe-epilepsy)
• [Prion Disease](/diseases/prion-disease)
• [Synaptic Plasticity](/mechanisms/synaptic-plasticity)

External Links

• [NCBI Gene 2709](https://www.ncbi.nlm.nih.gov/gene/2709)
• [UniProt O75771](https://www.uniprot.org/uniprot/O75771)
• [Ensembl ENSG00000162711](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000162711)
• [OMIM 604619](https://www.omim.org/entry/604619)

References